Pharmaceuticals & Therapeutics

A new clinical trial for a twice-yearly COPD injection could disrupt a multi-billion dollar market, offering hope to millions and validating a novel biotech strategy.

A patient with 'untreatable' colorectal cancer is disease-free for six years after a novel vaccine. But the real revolution may be the biopsy-free tech behind it.

With a new CFO skilled in scaling hardtech and a new deal-making chief, Fortera is signaling its move from the lab to the global market.

A new Philips report quantifies AI's benefits in healthcare, from saving time to catching errors. But the path to adoption is fraught with challenges.

A major U.S. fund's increased stake in KT&G signals deep trust in its global expansion, backed by record Q1 growth and a promise of richer dividends.

AMPERA is building a thorium supply chain from Australia to fuel its U.S. microreactors. It's a bold play to power the AI era on a long-promised, yet unproven, fuel.

A deadly, vaccine-less Ebola strain is spreading in Central Africa. As governments scramble, the CDC Foundation deploys its most potent weapon: agile funding.

A Stanford spinout just revealed a wearable that measures the body's master stress hormone in real time. This isn't just a new gadget; it's a fundamental shift.

Beyond shiny trophies, the Astra Play Awards are a strategic tool for independent retailers, revealing key trends in STEM, wellness, and the growing 'kidult' market.

With key hires Ulf Wiinberg and Bill MacKenzie, Neuraptive signals a major shift from R&D to market readiness for its nerve repair therapeutic, NTX-001.

The pest control specialist's Nasdaq debut is more than a ticker change. It’s a calculated gambit to tap U.S. capital and scale a resilient, niche industry.

A landmark drug approval in China offers new hope for IgAN patients. But the real story is how science, strategy, and policy are converging to build a better future.

A Berkeley startup is turning old clothes into virgin-quality materials using AI-designed enzymes. This isn't just recycling; it's a new economic model.

As National Outlet Shopping Day returns, it's more than a sale. It's Simon's blueprint for the future of retail and a key test of consumer spending.

BioCardia secures a crucial $4.4M, extending its runway for a key Japan submission. But a closer look reveals a high-stakes bet on future warrant exercises.

Promising early data for obesity drug DA-1726 shows rapid weight loss, while vanoglipel demonstrates powerful synergy in MASH and diabetes combination therapies.

Kymera Therapeutics' new lupus data isn't just about a drug. It's about a new strategy: erasing disease-causing proteins to build resilient value.

Phenomenex, a Danaher company, launches its Luna Omega HILIC columns, aiming to simplify complex analysis in pharma, food safety, and diagnostics.

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.

A new partnership between PAM Health and Marshall Health Network isn't just building a hospital; it's creating a new healthcare and economic hub for South Point.